Justin Stebbing MD PhD

Dr. Stebbing is a British clinician-scientist specializing in oncology and cancer research. He trained at Trinity College, Oxford, did his medicine residency at Johns Hopkins Hospital, USA and at the Royal Marsden, St Bart’s Hospitals. He was from 2009-2022 Professor of Oncology at Imperial College and published over 650 peer-reviewed papers. He has also been the  Principal Investigator on a large number of clinical studies of novel/innovative compounds.  During the pandemic, he led many of the mechanistic, laboratory and global studies leading to baricitinib’s FDA approval in November 2020. Dr. Stebbing was awarded the NIHR’s first research translational professorship, becoming Editor-in-Chief of Oncogene and elected a member of the American Society for Clinical Investigation.